ArticleJournal of neuro-oncology2014
Symptoms and medication management in the end of life phase of high-grade glioma patients.
Article in Journal of neuro-oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 58 citations in OpenAlex.
- Swallowing disorders and mortality in adults with advanced cancer outside the head and neck and upper gastrointestinal tract: a systematic review.BMC palliative care · 2023Pooled it
- Prevalence of symptoms in glioma patients throughout the disease trajectory: a systematic review.Journal of neuro-oncology · 2018Pooled it
- SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Guideline
- "It's a club nobody wanted to join, but we're there": Focus groups on end-of-life care experiences and long-term outcomes of bereaved neuro-oncology caregivers.Palliative care and social practice · 2026Article
- The impact of palliative care contact on the use of hospital resources at the end of life for brain tumor patients; a nationwide register-based cohort study.Journal of neuro-oncology · 2025Article
- A Review on the Application of Hospice Care in Patients with Advanced Cancer.Patient preference and adherence · 2023Review
- Diazepam diminishes temozolomide efficacy in the treatment of U87 glioblastoma cell line.CNS neuroscience & therapeutics · 2022Article
- Alignment between glioblastoma internal clock and environmental cues ameliorates survival in Drosophila.Communications biology · 2022Article
- Supportive care of patients diagnosed with high grade glioma and their carers in Australia.Journal of neuro-oncology · 2022Article
- Palliative care for patients with glioma: A recent scientometric analysis of the Web of Science in 2022.Frontiers in oncology · 2022Article
- Associations Between Hospice Care and Scary Family Caregiver Experiences.Journal of pain and symptom management · 2021Article
- The Korean Society for Neuro-Oncology (KSNO) Guideline for Antiepileptic Drug Usage of Brain Tumor: Version 2021.1.Brain tumor research and treatment · 2021Article
- Exploring sleep disturbance among adults with primary or secondary malignant brain tumors and their caregivers.Neuro-oncology practice · 2021Article
- End-of-life care for glioma patients; the caregivers' perspective.Journal of neuro-oncology · 2020Observational
- Symptom relief during last week of life in neurological diseases.Brain and behavior · 2019Article
- Scutellarin inhibits the metastasis and cisplatin resistance in glioma cells.OncoTargets and therapy · 2019Article
- End-of-Life Care in High-Grade Glioma Patients. The Palliative and Supportive Perspective.Brain sciences · 2018Review
- Supportive Care Needs in Glioma Patients and Their Caregivers in Clinical Practice: Results of a Multicenter Cross-Sectional Study.Frontiers in neurology · 2018Article
- Palliative and end-of-life care in glioblastoma: defining and measuring opportunities to improve care.Neuro-oncology practice · 2017Article
- Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma.Journal of pain and symptom management · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the end of life (EOL) phase of high-grade glioma (HGG) patients, care is primarily aimed at reducing symptom burden while maintaining quality of life as long as possible. In this study, we evaluated the prevalence of symptoms and medication management in HGG patients during the EOL phase. We analyzed disease-specific symptoms, general EOL symptoms, symptom frequency, and medication use at 3 months and 1 week before death in a cohort of 178 HGG patients, based on questionnaires completed by physicians responsible for EOL care. In addition, information on patient's perceived quality of care (QOC) was derived from 87 questionnaires completed by patient's relatives. Somnolence, focal neurological deficits and cognitive disturbances were the most prevalent symptoms during the EOL phase. Overall, disease-specific symptoms occurred more often than general EOL symptoms at both 3 months and 1 week before death. Somnolence and/or dysphagia were present in 81 % of patients whose medication was withdrawn and 96 % of patients in whom antiepileptic drugs (AEDs) were withdrawn. One week before death, 65.9 % of patients with high symptom frequency experienced good QOC, compared to 87.5 % of patients with low symptom frequency (p = 0.032). Disease-specific symptoms are the main concern in EOL care for HGG patients. Somnolence and dysphagia may hamper the regular oral administration of drugs, and particularly AEDs, during the EOL phase. High symptom frequency at 1 week before death negatively affects patient's perceived QOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.